1.A Case Report of Conn's Myopathy.
Bo Wan SUH ; Khyoung Yhun O ; Yeung Ju BYUN ; Choong Suh PARK ; Hong Jin KIM
Yeungnam University Journal of Medicine 1987;4(1):133-137
Myopathy in primary aldosteronism in relatively rare disease in Korea. A 42-year-old woman with hypokalemic periodic paralysis, proximal muscle weakness and hypertension was found to have myopathy associated with adenoma in the right adrenal gland. She showed marked elevation of muscle enzymes and myopathic pattern in EMG.
Adenoma
;
Adrenal Glands
;
Adult
;
Female
;
Humans
;
Hyperaldosteronism
;
Hypertension
;
Hypokalemic Periodic Paralysis
;
Korea
;
Muscle Weakness
;
Muscular Diseases*
;
Rare Diseases
2.Etiologic Factors and Prognosis of Delayed Postanoxic Encephalopathy.
Bo Wan SUH ; Young Ju BYUN ; Choong Suh PARK
Journal of the Korean Neurological Association 1987;5(1):49-55
Etiologic factors and prognosis of delayed postanoxic encephalopathy (DPE) was analyzed in 30 patients admitted in Yeungnam University Medical Center from March, 1984 to April, 1987. Twenty-three among the 30 cases was possible to be followed. The results are as follows. 1. The incidence in over 30 years of age was 77%, and sex ratio was 1:1.7 for male and female. 2. The lucid interval of DPE was from 5 to 191 days (mean=19 days) and interval between 3 to 4 weeks occupied 60%. 3. The longer the duration of exposure to CO and the more comatous of the mental state, the more increased was the incidence of DPE. 4. The hyperbaric O2 threapy had no influence on the incidence of DPE but absolute bed rest on acute CO poisoning ws important to prevent DPE. Therefore, absolute bed rest during lucid interval at least 2 weeks is more important factor to prevent DPE. 5. DPE victims are likely to retire from his social position.
Academic Medical Centers
;
Bed Rest
;
Female
;
Humans
;
Incidence
;
Male
;
Poisoning
;
Prognosis*
;
Sex Ratio
3.Can the Histoculture Drug Response Assay Predict the Clinical Results of Chemotherapy in Breast Cancer?.
Yong Sik JUNG ; Young Up CHO ; Young Jin SUH ; Jeong Soo KIM ; Se Jeong OH ; Cheol Wan LIM ; Moon Bo KIM ; Heung Kyu PARK
Journal of Breast Cancer 2007;10(3):193-198
PURPOSE: The behavior of invasive carcinomas in human can be very varied with different individual responses to chemotherapy. Individualization is crucial to the optimization of chemotherapy. Therefore, the prediction of a tumor's sensitivity to anticancer agents has been the subject of intensive investigation. In order to investigate the pathobiology of breast cancer, it is necessary to maintain or recreate the characteristics of the three-dimensional architecture of the tissues in culture. In this study, we have evaluated the relationship between the Histoculture Drug Response Assay (HDRA) assessment and chemotherapy responses in breast cancer patients. METHODS: Tumor specimens from 30 patients with breast cancer were evaluated using the HDRA. Tumor tissues were cultured on gelfoam sponge gel in 24-well plates, followed by treatment with a variety of chemotherapeutic agents. All treatments were conducted in triplicate. The sensitivity of a chemotherapy regimen was defined as a tumor inhibition rate (IR) in excess of 30%. Neoadjuvant or palliative chemotherapy for patients, using anthracycline or taxane, was conducted on the basis of the established protocols. The responses to treatments were compared with the results of the HDRA. RESULTS: The mean IR for the combinations of doxorubicin and docetaxel and for FAC and AC were 48, 45, and 36%, respectively. The above partial rate of response to chemotherapy was 81.1%. The sensitivity and specificity of the HDRA assessment, with a 30% inhibition rate, were 81.5 and 66.7%, respectively. The positive and negative response prediction values were 91.7 and 44.4%, respectively. The responses to treatments and the results of the HDRA assessment were not correlated with the expressions of the hormonal receptor or c-erbB2. CONCLUSION: In cases in which the inhibition rate is in excess of 30%, the HDRA assessment yielded a high positive response prediction value. The sensitivity to chemotherapy, as determined by the HDRA, appears to be a good guide for selection in breast cancer patients. Thus the results presented herein should be integrated into future research on the subject.
Antineoplastic Agents
;
Breast Neoplasms*
;
Breast*
;
Doxorubicin
;
Drug Therapy*
;
Gelatin Sponge, Absorbable
;
Humans
;
Porifera
;
Sensitivity and Specificity
4.Can the Histoculture Drug Response Assay Predict the Clinical Results of Chemotherapy in Breast Cancer?.
Yong Sik JUNG ; Young Up CHO ; Young Jin SUH ; Jeong Soo KIM ; Se Jeong OH ; Cheol Wan LIM ; Moon Bo KIM ; Heung Kyu PARK
Journal of Breast Cancer 2007;10(3):193-198
PURPOSE: The behavior of invasive carcinomas in human can be very varied with different individual responses to chemotherapy. Individualization is crucial to the optimization of chemotherapy. Therefore, the prediction of a tumor's sensitivity to anticancer agents has been the subject of intensive investigation. In order to investigate the pathobiology of breast cancer, it is necessary to maintain or recreate the characteristics of the three-dimensional architecture of the tissues in culture. In this study, we have evaluated the relationship between the Histoculture Drug Response Assay (HDRA) assessment and chemotherapy responses in breast cancer patients. METHODS: Tumor specimens from 30 patients with breast cancer were evaluated using the HDRA. Tumor tissues were cultured on gelfoam sponge gel in 24-well plates, followed by treatment with a variety of chemotherapeutic agents. All treatments were conducted in triplicate. The sensitivity of a chemotherapy regimen was defined as a tumor inhibition rate (IR) in excess of 30%. Neoadjuvant or palliative chemotherapy for patients, using anthracycline or taxane, was conducted on the basis of the established protocols. The responses to treatments were compared with the results of the HDRA. RESULTS: The mean IR for the combinations of doxorubicin and docetaxel and for FAC and AC were 48, 45, and 36%, respectively. The above partial rate of response to chemotherapy was 81.1%. The sensitivity and specificity of the HDRA assessment, with a 30% inhibition rate, were 81.5 and 66.7%, respectively. The positive and negative response prediction values were 91.7 and 44.4%, respectively. The responses to treatments and the results of the HDRA assessment were not correlated with the expressions of the hormonal receptor or c-erbB2. CONCLUSION: In cases in which the inhibition rate is in excess of 30%, the HDRA assessment yielded a high positive response prediction value. The sensitivity to chemotherapy, as determined by the HDRA, appears to be a good guide for selection in breast cancer patients. Thus the results presented herein should be integrated into future research on the subject.
Antineoplastic Agents
;
Breast Neoplasms*
;
Breast*
;
Doxorubicin
;
Drug Therapy*
;
Gelatin Sponge, Absorbable
;
Humans
;
Porifera
;
Sensitivity and Specificity
5.Association of Polymorphism in beta3-Adrenergic Receptor Gene with Fat Distribution.
Tae Sung YUN ; Yong Deuk KIM ; Hye Soon KIM ; Mi Jung KIM ; Young Sung SUH ; Jung Hyeok KWON ; Jin Soo CHOI ; Jung Guk KIM ; Sung Woo HA ; Bo Wan KIM ; Kyu Chang WON ; Hyong Woo LEE ; Ho Sang SHON ; Ji Hyun LEE ; Hyun Dae YOON ; Won Ho KIM ; Young Gil YUN ; In Kyu LEE
Journal of Korean Society of Endocrinology 2003;18(2):184-192
BACKGROUND: Reasons for obesity include environmental factors and, more largely so, genetic factors. There have been many studies on these genetic factors. So far, genes related to obesity such as Leptin, Uncoupling Protein(UCP), Peroxisome proliferator activated receptor-gamma(PPAR-gamma), and Beta3-adrener-gic receptor(beta3-AR) gene have been discovered. Among these, beta3-AR is expressed in visceral adipose tissue and is thought to contribute to the regulation of resting metabolic rate and lipolysis. The missense mutation of beta3-AR gene, resulting in replacement of tryptophan by arginine at position 64(Trp64Arg), is associated with decreased resting metabolic rate and weightgain. We performed this study to determine if Trp64Arg polymorphism of beta3-AR gene is associatedwith obesity in Koreans. METHOD: We investigated the relationship between the beta3-AR gene mutation and body mass index (BMI), waist circumference, hip circumference, waist to hip ratio(WHR), area of subcutaneous fat, area of visceral fat, visceral to subcutaneous fat ratio(VSR), and lipid profile. 198 subjects were included in this study of which 97 were of normal weight and 101 were obese. Anthropometric data was obtained from physical examination and medical records. RESULT: In the cases of beta3-AR gene mutation of the obese group, the ratio of Trp/Arg and Arg/Arg are 43% and 5%, respectively, which were higher than the normal group(36%, 1%), although a statistical significant was not found. There was significant difference in the are of subcutaneous fat. Normal group(Trp/Trp) measured at 213.9+/-109.6cm2 versus 244.0+/-127.7cm2 (Trp/Arg) and 323.9+/-189.9cm2(Arg/Arg) for the mutation groups. Circumference of waist, circumference of hip, WHR, area of visceral fat, and VSR were higher in the mutation groups than in normal subject, but not significantly different. CONCLUSION: These results suggest that a genetic mutation in the beta3-AR gene can affect body fat composition, and is associated with obesity in Korean adults.
Adipose Tissue
;
Adult
;
Arginine
;
Body Mass Index
;
Hip
;
Humans
;
Intra-Abdominal Fat
;
Leptin
;
Lipolysis
;
Medical Records
;
Mutation, Missense
;
Obesity
;
Peroxisomes
;
Physical Examination
;
Subcutaneous Fat
;
Tryptophan
;
Waist Circumference
6.Long-Term Results of a Hepatopancreatoduodenectomy for Biliary-Tract Cancer.
Jae Han JEONG ; Sung Gyu LEE ; Young Joo LEE ; Kwang Min PARK ; Shin HWANG ; Dong Lak CHOI ; Ki Hun KIM ; Chul Soo AHN ; Pyung Chul MIN ; Myung Hwan KIM ; Sung Koo LEE ; Dong Wan SUH ; Gyu Bo SUNG ; Hyun Gi YOON
Journal of the Korean Surgical Society 2000;58(5):694-701
PURPOSE: The majority of carcinomas of the biliary tract are often diagnosed at an advanced stage, despite improved diagnostic capabilities. Aggressive surgery is generally recommended in an attempt to cure the advanced disease because only complete resection of the tumor can provide a chance to improve the survival rate. Thus, the purpose of this research was to assess the effectiveness of a hepatopancreato duodenectomy (HPD) in patients with both advanced gallbladder cancer directly invading adjacent organs and diffuse bile-duct cancer by analyzing the long term results of an HPD. METHODS: Forty patients underwent an HPD at Asan Medical Center from December 1993 to May 1999, and their cases were retrospectively reviewed. Gallbladder cancers was present in 14 of the patients and bile-duct cancers in 24 cases; the other 2 cases were benign. Cancers were classified by using the criteria of the American Joint Commission on Cancer (AJCC). Survival curves were calculated by using the Kaplan-Meier method. The median follow-up was 35 months. RESULTS: Hepatectomies varied from a right trisegmentectomy to an S4aS5 subsegmentectomy. There were 19 (47.5%) major postoperative complications, including intraabdominal bleeding, intestinal obstruction, liver abscess, and others. Of the 14 patients experiencing tumor recurrence, 7 (50%) cases involved the remnant liver. There were 4 (10%) perioperative mortalities. The 5 (22.7%) patients who with stage IVa and IVb cancer (22 cases) survived more than 3 years are all still alive and without tumor recurrence. The 1-and 3-year cumulative survival rates for gallbladder cancer were 83.3% and 48.5%, respectively, and those for bile-duct cancer were 83.3% and 49.7%. The differences in survival between the groups was not statistically significant, excluding perioperative deaths. The median survival was 13.7 months. CONCLUSION: An HPD is indicated for either advanced gallbladdercancer or diffuse bile-duct cancer because complete resection through this surgical procedure can provide a chance to improve survival. It is necessary to decrease perioperative mortality and morbidity by complete preoperative evaluation, meticulous operative manipulation, and intensive postoperative care.
Biliary Tract
;
Chungcheongnam-do
;
Follow-Up Studies
;
Gallbladder Neoplasms
;
Hemorrhage
;
Hepatectomy
;
Humans
;
Intestinal Obstruction
;
Joints
;
Liver
;
Liver Abscess
;
Mortality
;
Postoperative Care
;
Postoperative Complications
;
Recurrence
;
Retrospective Studies
;
Survival Rate
7.Prospective Study on Success and Complication Rate of Central Venous Catheterization in a University-affiliated Hospital.
Chang Hwang BAE ; Woo Kun KIM ; Wan PARK ; Jin Hee PARK ; Jeong Kyun KIM ; Sung Jun CHOI ; Je Hwan LEE ; Sung Bae KIM ; Sang We KIM ; Cheolwon SUH ; Kyoo Hyung LEE ; Jung Shin LEE ; Younsuck KOH ; Kyu Bo SUNG ; Sang Hee KIM
Korean Journal of Medicine 1998;55(2):195-201
OBJECTIVES: The reported success rate of central venous catheterization ranged from 84% to 97.5%, and the complication rate from 0.3% to 12%. The most important contributing factor for complications reported by several authors was the physician's experience. We investigated the success and complication rates of central venous catheterization prospectively. We also evaluate the factors that contributed to complications at our institution as part of our quality assurance study. METHODS: Four hundred sixty five central venous catheterizations were conducted at the medical intensive care unit and the general ward of the hematology/ oncology Department of Asan Medical Center in Korea, from June to November, 1997. We surveyed the date and place of the procedures, ID numbers, age and sex of the patients, the training level of physicians, the types of catheters, initial puncture sites, success or failure, and complications. We grouped the purpose of procedures into 5 categories, such as hemodynamic monitoring, fluid therapy, chemotherapy, total parenteral nutrition, and others. RESULTS: The initial success rate, defined as the initial performer being able to insert the catheter without changing the skin puncture site, was 78.5%. The overall success rate for initial performers, including those who required multiple skin puncture sites, was 82.8%. The total success rate, including changing the performers (up to 4 performers), was 96.1%. The overall complication rate was 5.2% including pneumothorax (2.8%), hemothorax (0.2%), subcutaneous hematoma (1.1%), catheter tip malposition (0.9%), and air-embolism (0.2%). There were no differences in the complication rates with regards to the sex and age of the patient, initial puncture sites, the physician's training level between 1st and 2nd year residency, and vein localization. However, the complication rate differed significantly in relation to the number of initial punctures. Patients with 1-3 punctures had a complication rate of 4.3%, while patients with 4 or more punctures had a complication rate of 18.5%. CONCLUSION: The overall complication rate was 5.2% and pneumothorax occured in 2.8%. We expect that we can decrease the number of complications by taking over the procedure if the initial performer fails on the first or second attempt and by attempting the skin puncture not more than 4 times at initial trial.
Catheterization, Central Venous*
;
Catheters
;
Central Venous Catheters*
;
Chungcheongnam-do
;
Drug Therapy
;
Fluid Therapy
;
Hematoma
;
Hemodynamics
;
Hemothorax
;
Humans
;
Intensive Care Units
;
Internship and Residency
;
Korea
;
Parenteral Nutrition, Total
;
Patients' Rooms
;
Pneumothorax
;
Prospective Studies*
;
Punctures
;
Skin
;
Veins
8.DNA Methylation of RUNX3 in Papillary Thyroid Cancer.
Hee Ja KO ; Bo Yeon KIM ; Chan Hee JUNG ; Sung Wan CHUN ; Ji Oh MOK ; Yeo Joo KIM ; Hyeong Kyu PARK ; Chul Hee KIM ; Sang Jin KIM ; Dong Won BYUN ; Kyo Il SUH ; Myung Hi YOO ; Sung Gu KANG
The Korean Journal of Internal Medicine 2012;27(4):407-410
BACKGROUND/AIMS: The relationship between Runt-related transcription factor 3 (RUNX3) gene inactivation and various solid tumors has been reported; however, little information is available about RUNX3 in thyroid cancers. METHODS: We evaluated the DNA methylation of RUNX3 in 13 papillary thyroid cancer tissues and four thyroid cancer cell lines. Additionally, using reverse transcriptase-polymerase chain reaction, we analyzed RUNX3 gene expression in several thyroid cancer cell lines after treating with the demethylating agent 5-aza-2'-deoxycytidine (DAC). RESULTS: RUNX3 was hypermethylated in many thyroid cancer cell lines and in 10 of the 12 papillary thyroid cancer tissues. Treatment with DAC increased the expression of RUNX3 in some thyroid cancer cell lines. CONCLUSIONS: We suggest that RUNX3 is associated with thyroid carcinogenesis, and RUNX3 methylation is a potentially useful diagnostic marker for papillary thyroid cancer.
Azacitidine/analogs & derivatives/pharmacology
;
Carcinoma/*genetics
;
Cell Line, Tumor
;
Core Binding Factor Alpha 3 Subunit/*genetics
;
DNA Methylation/drug effects
;
Gene Expression/drug effects
;
Humans
;
Thyroid Neoplasms/*genetics
;
Tumor Markers, Biological/genetics
9.Review of Trochanteric approach in 285 Total Hip Arthroplasties
Young Yong KIM ; Myung Chul YOU ; Sang Wan LEE ; Chul Un KO ; Suck Hyun LEE ; Won Kap LEE ; Hyun Soo KIM ; Jin Whan AHN ; Keim Chul KIM ; Young Gun PARK ; Hye Duk KIM ; Moo Sam SUH ; Dal Bo SHIM ; Dong Sun LEE ; Byung Kyom SOH
The Journal of the Korean Orthopaedic Association 1977;12(4):619-626
This paper is a consecutive series of total hip arthroplasties were performed over 6 years period by the same group surgeons utilizing the Charnley method as well as the lateral approach with trochanteric osteo. tomy. Trochanteric reattachment was accomplished in 285 hips and method of reattachment were basically standard Charnley technique which we used in most of our series. In addition, some modification of original Charnley technique which we used in early this trial were also included for this study. As far as trochanteric complications are concerned, there are 18 cases of hips where there was wire breakage, proximal drift of greater trochanter and 6 established cases of nonunion also reported. By the use of wire mash, we have performed a revisional surgery which has re-inforced of the greater trochanter. This was the case when the greater trocyhanter was very osteoporotic. Finally, biomechanical considerations of the re-attachment of the greater trochanter and new Charnley staple clamp method were introduced with review of our cases and analysed for technical failures.
Arthroplasty
;
Femur
;
Hip
;
Methods
;
Surgeons
10.Correlation between serum prolactin levels and immunocytochemical findings of pituitary adenomas in patients with acromegaly.
Bo Hyun KANG ; In Kyung JEONG ; Duck Shin CHO ; Han Wook KANG ; Hyung Hoon KIM ; Beom Jin KIM ; Tae Hoon MIN ; Jun Seong SON ; Sung No HONG ; Choon Young LEE ; Byung Wan LEE ; Jeong Hyun NOH ; Jae Hoon CHUNG ; Yong Ki MIN ; Myung Shik LEE ; Moon Kyu LEE ; Kwang Won KIM ; Yeun Lim SUH
Korean Journal of Medicine 2003;64(2):197-203
BACKGROUND: Acromegaly occurs by excessive secretion of growth hormone and more than 99% of cases are caused by a growth hormone-secreting pituitary adenoma. Pituitary adenomas expressing multiple immunoreactivities are common. We assumed that the pituitary adenomas which is immunochemically detected growth hormone and prolactin are responsible for it and reviewed 28 patients with acromagaly to determine the correlation between serum hormonal level and immunocytochemical finding. METHODS: Twenty-eight patients with acromegaly who underwent surgery of pituitary adenoma in Samsung Medical Center from October 1998 to may 2001 were included. Baseline hormonal evaluations and several endocine tests were performed. Immunocytochemical stain was done. RESULTS: According to the extent of hormonal stain, the adenoma was divided into two groups. The adenoma showing immunoreactivity over 50% to growth hormone was 100%, to prolactin was 71.4% and to FSH was 25.0%. The extent of other hormonal stain was less than 20%. There were no significant differences in age, sex, the ratio of macroadenoma and microadenoma, the basal serum GH level, serum IGF-1 level, and the response to TRH, somatostatin and bromocriptine suppression test between the two groups divided by the the extent of prolactin stain. But the serum prolactin level was 55.0+/-63.4 ng/mL, and 19.9+/-12.2 ng/mL each in two groups which was siginificantly increased in the adenoma showing immunoreactivity over 50% to prolactin. CONCLUSION: Acromegaly patients with higher expression of prolactin on immunocytochemical studies showed higher serum prolactin levels and patients with hyperprolactinemia showed higher serum IGF-1.
Acromegaly*
;
Adenoma
;
Bromocriptine
;
Growth Hormone
;
Growth Hormone-Secreting Pituitary Adenoma
;
Humans
;
Hyperprolactinemia
;
Insulin-Like Growth Factor I
;
Pituitary Neoplasms*
;
Prolactin*
;
Somatostatin